Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Abstract Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment paradigms for hematological malignancies. However, more than half of these patients cannot achieve sustainable tumor control, partially due to the inadequate potency of CAR-T cells in eradicating tumor cells. T...
Saved in:
| Main Authors: | Zhongfei Tao, Zuzana Chyra, Jana Kotulová, Piotr Celichowski, Jana Mihályová, Sandra Charvátová, Roman Hájek |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-12-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-01193-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-T Therapy Beyond B-Cell Hematological Malignancies
by: Martina Canichella, et al.
Published: (2025-01-01) -
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
by: Raphaël Stadelmann, et al.
Published: (2022-10-01) -
PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies
by: Shashi B. Singh MBBS, et al.
Published: (2024-05-01) -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
by: Ugo Testa, et al.
Published: (2024-02-01) -
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01)